OUR EXPERTS

Epidemiology, Biostatistics, and Pharmaceutical Commercialization

Meet some of the renowned scientists, physicians, and engineers who help BlueRidge clients achieve their most important life science goals.

Swipe to learn more about our experts

  • Philip Cyr, MPH

    SENIOR VICE PRESIDENT
    Pharmaceutical Commercialization

    My specialty is developing and communicating health economic and outcomes research evidence, pricing strategies, and interacting with medical affairs professionals and payers for over 30 years across a wide range of therapeutic areas. Specific expertise in advanced therapies having supported > 30 cell and gene therapies including 10 that have been approved on the market.

  • Ivar Jensen, MBA

    VICE PRESIDENT
    Pharmaceutical Commercialization

    My specialty is in health economic modeling and value demonstration. With over 20 years of experience, I lead teams to develop robust, rigorous and evidence-based health economic models for pharmaceutical, biopharmaceutical, diagnostic, and medical device companies. My expertise spans a wide range of therapeutic areas including rare diseases and gene therapies. I am committed to partnering with clients to ensure their products demonstrate value and achieve success. 

  • Heidi Reichert, MA

    DIRECTOR & MANAGING STATISTICIAN
    EpidStrategies

    I specialize in the application of statistical methods and programming to real world and clinical trial data. I have more than 25 years of experience as a consultant, 18 of those as a statistician. My goal on every project is to work with the client to design studies that answer their research question and to provide clear and transparent analyses with interpretable results.

  • Naomi Sacks, PhD

    VICE PRESIDENT
    Pharmaceutical Commercialization

    My specialty is in developing and disseminating evidence that advances access for emerging therapies. I bring over 30 years in health economics and outcomes research, data analytics, and therapy commercialization to projects that quantify product value for multiple stakeholders. I work across therapeutic areas, including rare and ultra rare, neglected, and prevalent indications. As a partner, I  work collaboratively with clients to develop and implement robust solutions that address their strategic needs.

  • Mina Suh, MPH

    SUPERVISING EPIDEMIOLOGIST
    EpidStrategies

    My expertise lies in public health research strategy, planning, and execution. My work in infectious disease has been used and cited by many organizations including the CDC. Using my knowledge and extensive research experience in epidemiology, I am passionate about developing studies to meet the needs of patients and improving their lives.